Onboarding new oncology patients can be a delicate process to help them prepare for their care journey. Here are the first steps.
When patients receive a cancer diagnosis, they’re reeling emotionally. Thus, there’s no “right time” to welcome them to your practice.
In response, Northwest Medical Specialties in Puyallup, Washington, has structured its process of welcoming patients and setting expectations for the care journey ahead.
Following are three things the multispecialty practice does to ease patients into their care journey:
Northwest Medical Specialties’ welcome binder is faux-leather bound and has the practice’s logo embossed on it.
The binder is structured as a tool for the patient to keep track of the records that document their care in the practice. The practice chose a faux-leather cover for two reasons: It looked important and official while not costing a lot of money.
Organized by sections, the binder orients patients about who to call and when and where they call if, for example, they have a fever or experience other treatment-related side effects.
Jessa Dunivan, patient services manager, says that patients who have recently received a cancer diagnosis remember 20% of what they’re told when they first arrive at the practice. That’s because it can be an emotionally overwhelming experience. The welcome binder, which patients can access at home or during their visits, is a useful resource if their fever spikes or they experience nausea or vomiting.
2. Carve out time to welcome new patients
New patients are met by their care navigator for 30 minutes. That’s before they have their initial visit with their oncologist, says Dunivan.
This allows the care navigator to establish trust with a patient, she adds. A practical way to get a patient to open up in this first meeting is to ask an open-ended question, such as “What do you need help with?” If the patient says she needs help opening her mail, do that for her, recommends Dunivan.
A patient may have lost their job or not have transportation to and from appointments-and both scenarios can have an impact on their health. That’s why you need to ask open-ended questions, she adds.
Sometimes patients are so overwhelmed that they’ll politely refuse this initial face-to-face meeting with their care navigator or they’ll just stare with a blank look on their face. With these patients, Dunivan provides a brief introduction to the practice and the welcome binder and then follows up in a few days to ask if they’ve had a chance to review it.
3. Be open-minded
Dunivan says she doesn’t look at the patient’s diagnosis before she participates in one of the welcome visits. She doesn’t want to skew her perception of the patient and their needs. Her job, she says, is to make sure the patient knows she’s there to help them navigate through their journey at the practice.
This is also important for patients’ families, she says. They want to know that someone at the practice cares about their loved one and that if an issue comes up-such as distress or financial stress related to their cancer treatment-that she will help connect them with the right resources.
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More